



Ab Initio Whole Cell Kinetic Model of *Streptococcus equi* subsp. *zooepidemicus* SEZ13 (seqSA26)

Shamsia Bte Ali^{1,2}, Shnan Harish Modankap^{1,2}, Jullean Louise Dizon Baylon^{1,2}, Lavanya Dhingra^{1,2}, Nurhaliza Mohamed Ali^{1,2}, Parkavi Subramanian^{1,2}, Maurice Han Tong Ling^{2,3,4}

¹Department of Applied Sciences, Northumbria University, United Kingdom

²Management Development Institute of Singapore, Singapore

³Newcastle Australia Institute of Higher Education, University of Newcastle, Australia

⁴HOHY PTE LTD, Singapore

Corresponding Author: Maurice Han Tong Ling, Management Development Institute of Singapore, Singapore.

Received: May 22, 2026; **Published:** May 27, 2026

Abstract

Streptococcus equi subsp. *zooepidemicus* (SEZ) is a Gram-positive opportunistic pathogen that is recognised for its natural capacity to produce hyaluronic acid through fermentation; hence, may be a candidate for metabolic engineering. Although both genome scale metabolic models (GSMs) and kinetic models (KMs) inform metabolic engineering strategies, KMs are more advantageous than GSMs as it captures dynamic concentration changes. While a GSM of SEZ has been recently published, there is no KM of SEZ to-date. This study reports the *ab initio* construction of a whole-cell kinetic model for SEZ strain SEZ13 by identifying enzymatic genes from the annotated genome and mapping them into reactions in KEGG database. The resultant model, seqSA26, comprises 580 metabolites, 325 enzymes and 861 enzymatic reactions. Our results suggest that seqSA26 can be simulated and exhibit dynamic fluctuations of metabolite concentrations rather than flat lines, indicating a coherent network structure; therefore, establishing a draft model for future refinements, including growth coupling and improved resource allocation simulations.

Keywords: Kinetic model; Whole cell model; *Ab initio* modelling; Ordinary differential equations, AdvanceSyn Toolkit

Introduction

Streptococcus equi subsp. *zooepidemicus* (SEZ; commonly known as *Streptococcus zooepidemicus*) is a Gram-positive, encapsulated, beta-haemolytic bacterium [1] categorised as Lancefield group C streptococci [2]. SEZ is primarily recognised in veterinary medicine as an opportunistic pathogen [3] but it has recently garnered significant industrial interest because of its innate ability to produce hyaluronic acid (HA) [4]. HA is essential in specialised medical procedures like ocular surgery (e.g., cataract extraction and corneal transplantation), viscosupplementation for osteoarthritis, and accelerated wound healing, along with it being a main constituent in dermal fillers in cosmetic plastic surgery procedures due to its biocompatibility and hygroscopic properties [4]. Traditionally, HA was extracted from animal-derived sources, such as rooster combs or bovine vitreous humour; there is a risk of cross-species contamination and allergenicity [5]. Therefore, microbial fermentation using SEZ offers a highly pure, non-animal-derived, scalable source of HA, reducing the risk of pathogenic transmission and providing consistent product quality in the biotechnology industry [6].

Recently, type I-C CRISPR-Cas system may potentially allow improved production of HA through the knockout of the hyaluronidase gene to prevent HA product degradation [7]; thus, opening potential novel metabolic engineering of SEZ.

The design of metabolic engineering strategies typically begins with mathematical modelling to identify promising directions [8, 9]. Two frameworks are most widely used [10, 11]: GSMs and KMs. Although GSMs have shaped much of the field, their predictions emphasise rates rather than yields. KMs overcome this limitation by modelling both aspects [12], and enabling easier *in silico* gene knock-ins [13]. As a result, KMs offer a more complete platform for evaluating engineering strategies computationally. This has fuelled a growing movement within the field to invest more effort into constructing comprehensive kinetic models that can better support decision-making [14, 15].

Although a GSM of SEZ has been recently constructed specifically to study the production of HA (iZN522 [16]), there is no KM of SEZ to-date. As such, this study aims to construct a KM of *S. zooepidemicus*

SEZ13 using *ab initio* approach by identifying enzymes from its annotated genome, and identifying the corresponding reaction from KEGG [17]. The result is a whole cell KM of *S. zooepidemicus* SEZ13, named as seqSA26 using the nomenclature proposed by Cho and Ling [18], which consists of 580 metabolites, 325 enzymes with corresponding transcriptions and translations, and 861 enzymatic reactions.

Materials and Methods

Identification of Reactome. The genome of *Streptococcus zooepidemicus* strain SEZ13 (NCBI RefSeq assembly GCF_015689395.1; NCBI GenBank Accession NZ_CP065054.1) was used as source to identify enzymatic genes using the process previously described [13, 19, 20]. Briefly, each enzymatic gene was identified as a presence of complete Enzyme Commission (EC) number in the GenBank record and mapped into reaction IDs via KEGG Ligand Database for Enzyme Nomenclature [17]. For example, EC 1.1.1.23 (<https://www.genome.jp/entry/1.1.1.23>) catalyses reactions R01158, R01163, and R03012; where the substrates and products of each reaction can be identified.

Model Development. The model was developed using the ordinary differential equation (ODE) formats described in Sim et al. [21]. BioNumbers show that *Escherichia coli* harbours roughly 3000 RNA polymerases (BioNumbers 106199) [22], 25% of which actively elongate transcripts (BioNumbers 111676) [23] at 22 nucleotides per second (BioNumbers 104109) [24]. The average ribonucleotide weighs 339.5 Da, allowing an estimate of ~5600 kDa per second of mRNA produced, or 9.3e-18 grams per second. Factoring in a cellular volume of 7e-16 litres [25] and 4225 protein-coding genes (BioNumbers 105443) [26] gives an approximate synthesis rate of 2.92 micromolar per gene per second. Given a transcript lifespan of 107.56 s (BioNumbers 107666) [27] (0.93% decay per second), we arrive at: $d[\text{mRNA}]/dt = 0.00292 - 0.0093[\text{mRNA}]$. Protein synthesis proceeds at 0.278 peptides per transcript per second (BioNumbers 106382) [28], and protein turnover operates at about 2.78e-1 per second (BioNumbers 109924) [29], giving: $d[\text{peptide}]/dt = 0.278[\text{mRNA}] - 0.0000278[\text{peptide}]$. The biochemical reactome was represented as ODEs [19, 30] with enzyme parameters taken from Bar-Even et al.'s median survey [31] and formatted according to AdvanceSyn Model Specification [32].

Model Simulation. The constructed model was tested for simulatability using AdvanceSyn Toolkit [32]. Initial concentrations of all mRNA and enzymes were set to 0 mM. Initial concentrations of all metabolites were set to 1 mM except the following which were set to 1000 mM: (I) C00001 (Water), (II) C00002 (ATP), (III) C00003 (NAD+), (IV) C00004 (NADH), (V) C00005 (NADPH), (VI) C00006 (NADP+), (VII) C00007 (Oxygen), (VIII) C00011 (Carbon Dioxide), (IX) C00014 (Ammonia), (X) C00025 (L-Glutamate), (XI) C00031 (D-Glucose), (XII) C00037 (Glycine), (XIII) C00041 (L-Alanine), (XIV) C00047 (L-Lysine), (XV) C00049 (L-Aspartate), (XVI) C00064 (L-Glutamine), (XVII) C00065 (L-Serine), (XVIII) C00073 (L-Methionine), (XIX) C00097 (L-Cysteine), (XX) C00133 (D-Alanine), (XXI) C00148 (L-Proline). The model was simulated using the fourth-order Runge-Kutta method [33, 34] from time zero to 3600 seconds with timestep of 0.1 second, and the concentrations of metabolites were bounded between 0 millimolar and 1000 millimolar. The simulation results were sampled every 2 seconds.

Results and Discussion

The NCBI Prokaryotic Genome Annotation Pipeline (PGAP) predicts that SEZ has 2030 genes, where only 1933 genes are coding for proteins. 325 unique EC numbers consisting of 861 enzymatic reactions involving

580 metabolites were identified and developed into a model based on AdvanceSyn Model Specification [32]. In addition, 650 ODEs acting as placeholder for enzyme transcriptions and translations were added.

We ran seqSA26 through AdvanceSyn Toolkit [32], and the resulting simulation (Figure 1) confirms that the model executes correctly, with no evident syntax or compilation errors; as (a) the successful generation of simulation results demonstrates that the model can be simulated, and (b) the presence of fluctuations in simulated metabolite concentrations (rather than straight lines) implies that the metabolites respond to each other's concentrations. Given the intricacy of whole-cell models, successful runs are essential to demonstrate that the network structure is coherent. The simulation result is driven by the use of median kinetic constants [33] across all enzymes, a deliberate simplification to validate structure before parameter refinement. Accordingly, these outcomes should be regarded only as structural tests as argued in recent model constructions rather than direct representation within the cell [13, 20, 35–39]. Therefore, the key deliverable is a functioning whole-cell kinetic model for *S. zooepidemicus* SEZ13, serving as a flexible template for further expansion, such as adding growth coupling, variable enzyme kinetics, or resource allocation simulations [40–42].




Figure 1. Selection of Simulation Results.

Panel A shows the full simulation results (3600 seconds) of seven metabolites while Panel B zooms into the first 360 seconds.

Conclusion

In this study, we present an *ab initio* whole cell kinetic model of *Streptococcus zooepidemicus* strain SEZ13. The resulting kinetic model, seqSA26; comprising of 580 metabolites, 325 enzymes with corresponding transcriptions and translations, and 861 enzymatic reactions.

Supplementary Materials

Reaction descriptions and model can be downloaded from <https://bit.ly/seqSA26>.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors wish to thank the institute, Management Development Institute of Singapore, for its support towards this work. The cost of publication fees was borne by the authors.

References

- Xie H, Zhang R et al; (2024) "Characterization of AI-2/LuxS Quorum Sensing System in Biofilm Formation, Pathogenesis of *Streptococcus equi* subsp. *Zooepidemicus*". *Frontiers in Cellular and Infection Microbiology* 14: pp1339131.
- Beres SB, Sesso R, et al; (2008) "Genome Sequence of a Lancefield Group C *Streptococcus zooepidemicus* Strain Causing Epidemic Nephritis: New Information about an Old Disease". *PLoS One* 3(8): ppe3026.
- Cito F, Di Francesco CE, et al; (2025) "*Streptococcus equi* subsp. *zooepidemicus*: Epidemiological and Genomic Findings of an Emerging Pathogen in Central Italy". *Animals: an open access journal from MDPI* 15(10): pp1351.
- Marwan-Abdelbaset E, Samy-Kamal M, et al; (2025) "Microbial Production of Hyaluronic Acid: The Current Advances, Engineering Strategies and Trends". *Journal of Biotechnology* 403: pp52–72.
- Ciriminna R, Scurria A, et al; (2021) "Microbial Production of Hyaluronic Acid: The Case of an Emergent Technology in the Bioeconomy". *Biofuels, Bioproducts and Biorefining* 15(6): pp1604–1610.
- Ucm R, Aem M et al; (2022) "Comprehensive Review on Biotechnological Production of Hyaluronic Acid: Status, Innovation, Market and Applications". *Bioengineered* 13(4): pp9645–9661.
- Xie H, Zhang R, et al; (2024) "Endogenous Type I-C CRISPR-Cas System of *Streptococcus equi* subsp. *zooepidemicus* Promotes Biofilm Formation and Pathogenicity". *Frontiers in Microbiology* 15: pp1417993.
- Khanijou JK, Kulyk H et al; (2022) "Metabolomics and Modelling Approaches for Systems Metabolic Engineering". *Metabolic Engineering Communications* 15: ppe00209.
- Gudmundsson S, Nogales J et al; (2021) "Recent Advances in Model-Assisted Metabolic Engineering". *Current Opinion in Systems Biology* 28: pp100392.
- Richelle A, David B, et al; (2020) "Towards a Widespread Adoption of Metabolic Modeling Tools in Biopharmaceutical Industry: A Process Systems Biology Engineering Perspective". *npj Systems Biology and Applications* 6(1): pp 6.
- Lee YQ, Choi Y-M, et al; (2025) "Genome-scale metabolic model-guided systematic framework for designing customized live biotherapeutic products". *NPJ systems biology and applications* 11(1): pp73.
- Prabhu S, Kosir N, et al; (2025) "Derivative-Free Domain-Informed Data-Driven Discovery of Sparse Kinetic Models". *Industrial & Engineering Chemistry Research* 64(5): pp2601–2615.
- Yeo KY, Arivazhagan M, et al; (2025) "Ab Initio Whole Cell Kinetic Model of *Yarrowia lipolytica* CLIB122 (yliYKY24)". *Medicon Medical Sciences* 8(4): pp01–06.
- Foster CJ, Wang L, et al; (2021) "Building Kinetic Models for Metabolic Engineering". *Current Opinion in Biotechnology* 67: pp35–41.
- Lázaro J, Wongprommoon A, Júlvez J, Oliver SG et al; (2025) "Enhancing genome-scale metabolic models with kinetic data: resolving growth and citramalate production trade-offs in *Escherichia coli*". *Bioinformatics Advances* 5(1): ppvbf166.
- Nikuiyan Z, Tabandeh F, et al; (2025) "Reconstruction of a Genome-Scale Metabolic Model for *Streptococcus zooepidemicus*: Comparison with *Corynebacterium glutamicum* to Study Hyaluronic Acid Production". *PLoS One* 20(12): ppe0335509.
- Okuda S, Yamada T, et al; (2008) "KEGG Atlas mapping for global analysis of metabolic pathways". *Nucleic Acids Research (Web Server issue)*: W423–W426.
- Cho JL, Ling MH et al; (2021) "Adaptation of Whole Cell Kinetic Model Template, UniKin1, to *Escherichia coli* Whole Cell Kinetic Model, ecoJC20". *EC Microbiology* 17(2): pp254–260.
- Kwan ZJ, Teo W et al; (2024) "Ab Initio Whole Cell Kinetic Model of *Stutzerimonas balearica* DSM 6083 (pbmKZJ23)". *Acta Scientific Microbiology* 7(2): pp28–31.
- Maiyappan S, Sim SS, et al; (2025) "Four Ab Initio Whole Cell Kinetic Models of *Bacillus subtilis* 168 (bsuLL25) 6051-HGW (bshSM25), N33 (bsuN33SS25), FUA2231 (bsuGR25)". *Journal of Clinical Immunology & Microbiology* 6(2): pp1–6.
- Sim BJH, Tan NTF, Ling MHT et al; (2025) "Multilevel Metabolic Modelling Using Ordinary Differential Equations. Encyclopedia of Bioinformatics and Computational Biology (Second Edition), eds Ranganathan S, Cannataro M, Khan AM (Elsevier, Oxford)", pp 491–498.
- Müller-Hill B (1996) "The lac Operon: A Short History of a Genetic Paradigm (Berlin, Germany)".
- Churchward G, Bremer H, Young R (1982) "Transcription in Bacteria at Different DNA Concentrations". *Journal of Bacteriology* 150(2): pp572–581.
- Gray WJ, Midgley JE et al; (1971) "The Control of Ribonucleic Acid Synthesis in Bacteria. The Synthesis and Stability of Ribonucleic Acid in Rifampicin-Inhibited Cultures of *Escherichia coli*". *The Biochemical Journal* 122(2): pp161–169.
- Kubitschek HE et al; (1990) "Cell Volume Increase in *Escherichia coli* After Shifts to Richer Media". *Journal of Bacteriology* 172(1): pp94–101.
- Hu P, Janga SC, et al; (2009) "Global Functional Atlas of *Escherichia coli* Encompassing Previously Uncharacterized Proteins". *PLoS biology* 7(4): ppe96.
- So L-H, Ghosh A, et al; (2011) "General Properties of Transcriptional Time Series in *Escherichia coli*". *Nature Genetics* 43(6): pp554–560.

28. Schwanhäusser B, Busse D et al; (2013) “Corrigendum: Global Quantification of Mammalian Gene Expression Control”. *Nature* 495(7439): pp126–127.
29. Maurizi MR (1992) “Proteases and Protein Degradation in *Escherichia coli*”. *Experientia* 48(2): pp178–201.
30. Murthy MV, Balan D et al; (2020) “UniKin1: A Universal, Non-Species-Specific Whole Cell Kinetic Model”. *Acta Scientifica Microbiology* 3(10): pp04–08.
31. Bar-Even A, Noor E et al; (2011) “The Moderately Efficient Enzyme: Evolutionary and Physicochemical Trends Shaping Enzyme Parameters”. *Biochemistry* 50(21): pp4402–4410.
32. Ling MH et al; (2020) “AdvanceSyn Toolkit: An Open Source Suite for Model Development and Analysis in Biological Engineering”. *MOJ Proteomics & Bioinformatics* 9(4): pp83–86.
33. Yong B et al; (2019) “The Comparison of Fourth Order Runge-Kutta and Homotopy Analysis Method for Solving Three Basic Epidemic Models”. *Journal of Physics: Conference Series* 1317: pp012020.
34. Ling MH et al; (2016) “COPADS IV: Fixed Time-Step ODE Solvers for a System of Equations Implemented as a Set of Python Functions”. *Advances in Computer Science: an International Journal* 5(3): pp5–11.
35. Saisudhanbabu T, Yeo KY et al; (2025) “Ab Initio Whole Cell Kinetic Model of *Limosilactobacillus fermentum* EFEL6800 (IfeTS24)”. *EC Clinical and Medical Case Reports* 8(4): pp01–04.
36. Arivazhagan M, Senthilkumar A et al; (2025) “Ab Initio Whole Cell Kinetic Model of *Bifidobacterium bifidum* BGN4 (bbfMA24)”. *Acta Scientifica Nutritional Health* 9(1): pp42–45.
37. Senthilkumar A, Madhunisha A, et al; (2025) “Ab Initio Whole Cell Kinetic Model of *Lactobacillus acidophilus* NCFM (IacAS24)”. *Journal of Clinical Immunology & Microbiology* 6(1): pp1–5.
38. Wong TB, Le MA, et al; (2025) “Ab Initio Whole Cell Kinetic Models of *Escherichia coli* BL21 (ebeTBSW25) and MG1655 (ecoMAL25)”. *Scholastic Medical Sciences* 3(2): pp01–04.
39. Ambel WB, Tan LP, et al; (2025) “UniKin2 – A Universal, Pan-Reactome Kinetic Model”. *International Journal of Research in Medical and Clinical Science* 3(2): pp77–80.
40. Ahn-Horst TA, Mille LS, et al; (2022) “An Expanded Whole-Cell Model of *E. coli* Links Cellular Physiology with Mechanisms of Growth Rate Control”. *npj Systems Biology and Applications* 8(1): pp30.
41. Chagas M da S, Trindade Dos Santos M, et al; (2023) “Boolean Model of the Gene Regulatory Network of *Pseudomonas aeruginosa* CCBH4851”. *Frontiers in Microbiology* 14: pp1274740.
42. Hao T, Song Z, et al; (2024) “Reconstruction of Metabolic-Protein Interaction Integrated Network of *Eriocheir sinensis* and Analysis of Ecdysone Synthesis”. *Genes* 15(4): pp410.